Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Ligand Pharmaceuticals Inc

+ Add to Watchlist

LGDN:GR

65.977 EUR 2.945 4.67%

As of 10:43:02 ET on 03/27/2015.

Snapshot for Ligand Pharmaceuticals Inc (LGDN)

Open: 63.934 Day's Range: 63.257 - 65.977 Volume: 15
Previous Close: 63.032 52wk Range: 32.737 - 71.998 1-Yr Rtn: +35.19%

Stock Chart for LGDN

No chart data available.
  • LGDN:GR 65.977
  • 1D
  • 1M
  • 1Y
63.032
Interactive LGDN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for LGDN

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 33.2353
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) 2.1650
Est. PEG Ratio 1.1078
Market Cap (M EUR) 1,295.78
Shares Outstanding (M) 19.64
30 Day Average Volume 254
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend (USD) 15.0000
Dividend Ex-Date 04/03/2007
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for LGDN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for LGDN

Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.

John L HigginsChief Executive OfficerMatthew W Foehr "Matt"President/COO
Charles S BerkmanVP/Secretary/General CounselNishan De SilvaVP:Finance & Strategy/CFO
More Company Profile & Key Executives for LGDN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil